AI Startup OpenEvidence Hits $12B Valuation—What They Did Next Will Shock You!

OpenEvidence, an innovative artificial intelligence startup based in Miami, Florida, has recently garnered significant attention after closing a funding round that doubled its valuation to an impressive $12 billion. Known colloquially as "ChatGPT for doctors," OpenEvidence trains its chatbots using data derived from leading scientific journals, emphasizing its commitment to enhancing the healthcare landscape.

The company successfully raised $250 million in this latest financing round, led by Thrive Capital and DST, as reported by The Post and previously noted by CNBC. This follows a fundraising debut in February, when it attracted $75 million from Sequoia Capital at a $1 billion valuation, and a subsequent rise to a $6 billion valuation by October.

Founded in 2022 by billionaire poet and tech entrepreneur Daniel Nadler—who previously sold his company, Kensho Technologies, to Standard & Poor’s for $700 million in 2018—and Zachary Ziegler, a former PhD student at Harvard specializing in AI, OpenEvidence has quickly made waves in the health tech sector. The company claims that over 50% of physicians already utilize its tool, indicating a robust acceptance within the medical community. Nadler notes, “If you only squint from a distance, OpenEvidence is ‘ChatGPT’ for doctors. If you look closely, it’s a very different organism.”

OpenEvidence is designed specifically for physicians, offering a free yet professional-grade tool that focuses on specialized medical content through partnerships with esteemed publications like the New England Journal of Medicine. Nadler emphasizes the platform’s unique value, stating, “We’ve already gathered hundreds of millions of real-world clinical consultations from verified physicians—this feedback loop is incredibly hard to replicate.”

In the broader context, the U.S. healthcare market is a massive sector, accounting for nearly 20% of the country's gross domestic product (GDP), with an annual spending of around $5 trillion. Nadler believes that this expansive market presents ample growth opportunities, stating, “Health care is the largest segment of the real economy. People realize there could be a lot of winners in the space.”

While competitors like OpenAI have already launched HIPAA-compliant versions of their chatbots, including ChatGPT Health and Claude Healthcare, Nadler asserts that OpenEvidence's extensive data sets give it a competitive edge. The company's revenue model relies on advertising, which contrasts with other players like OpenAI. Nadler revealed that OpenEvidence achieved more than $100 million in annualized revenue last year, primarily through organic growth, with a staggering 95% of new users learning about the app from recommendations by other doctors.

Nadler has also expressed a desire to maintain OpenEvidence's independence amidst a landscape of significant acquisitions among AI giants. “We’re trying to be more disciplined than some companies that are openly planning to burn billions or tens of billions over the next several years,” he remarked. He is waiting for larger companies like SpaceX and OpenAI to go public before considering an IPO for OpenEvidence, believing that “there’s an order to nature” in the market.

As OpenEvidence continues to grow, it represents a burgeoning intersection of technology and healthcare, one that could potentially redefine how medical professionals access and utilize information. With an emphasis on real-world data and a commitment to serving smaller practices that often lack extensive IT resources, OpenEvidence is poised to play a significant role in the future of healthcare delivery in the United States.